New hope for rare disease patients: Rs 900-cr govt project to get high-value drugs at lower rates in works

Posted on:
Key Points

New Delhi: The Union health ministry is working on a Rs 900-crore mega initiative to procure high-value drugs in bulk for some rare diseases, which can be life-threatening and chronic, and medicines for which are prohibitively expensive, ThePrint has learnt...

The first-ever plan of its kind has been devised following a nudge by the Delhi High Court to ensure that when patients contract rare diseases for which drugs are available, they are not denied treatment, and they can effectively reap the benefits of the Centres National Policy for Rare Diseases, 2021...

Following recommendations by a high-level committee chaired by Dr Rajiv Bahl, director general of the Indian Council of Medical research (ICMR), the government negotiated with a few multinational drugmakers to procure bulk drugs for some priority rare diseases at lower rates, senior officials in the health ministry told ThePrint...

Senior government functionaries have also acknowledged that it is a worrying fact that few patients, compared to the large number of rare disease patients in need of crucial and innovative therapies, are receiving help.. we realise that even this (the financial aid for rare disease patients) is not sufficient as we dont want to leave any patient behind, L Swasticharan, additional deputy director general of the directorate general of health services in the health ministry, had said last month during the National Conference on spinal muscular atrophy organised by CureSMA...

Health ministry officials quoted earlier said the plan on bulk procurement of drugs for rare diseases would be rolled out this year after finalising the blueprint on how the drugs will be disbursed to needy patients...

You might be interested in

GST waiver may have limited benefit for patients; MNCs ask govt to extend it to all life-saving drugs sold here

13, Jul, 23

India Business News: Mumbai: The GST and customs duty waiver on drugs for rare diseases may only have a limited benefit for patients, as it is not applicable on drugs comm.

Delhi High Court steps in for patients of rare diseases, sets up panel to implement Centre’s policy

28, May, 23

The Delhi High Court has set up a five-member panel to implement the Centre’s rare diseases policy in an efficient manner and ensure that its benefits reaches patients.

Centre exempts basic customs duty on imported drugs for all rare diseases. Details here

30, Mar, 23

The exemption will result in substantial cost savings and provide much needed relief to the patients.

Fabry disease: Advocacy group seeks Health Ministry's intervention

30, Apr, 23

Patients of Fabry disease in India are calling for equal recognition under the National Policy for Rare Diseases 2021. Advocacy group, Lysosomal Storage Disorders Society of India, have urged Union Health Minister Mansukh Mandaviya to provide guidelines for CoEs to treat all notified disease conditions, including Fabry disease. The rare disease is caused by enzyme deficiencies affecting the functionality of the heart and kidneys, with the diagnosis rate remaining low due to low awareness.

First 4 made-in-India drugs for rare diseases launched, 4 more in pipeline, announces govt

24, Nov, 23

All drugs used for treating rare diseases were so far being imported & were prohibitively expensive. Health ministry says new drugs will bring down costs by up to 100-fold.

Despite help from Centre, patients with rare diseases, kin continue to suffer

12, Apr, 23

Rare diseases are lifelong conditions. Approximately 95 per cent of them have no approved treatment. In cases where drugs are available, they are prohibitively exorbitant. Fakir, who earns less than Rs 10,000 per month, says his son's treatment costs Rs 30 lakh per annum.

ICMR calls for development of local drugs for rare diseases, offers assistance in clinical research

26, Feb, 24

New Delhi: India’s leading health research body, the Indian Council of Medical Research (ICMR), has extended an invitation to domestic pharmaceutical and biotechnology companies to foster the development of localised treatments for a list of “priority rare genetic disorders”, ThePrint has learnt. This initiative follows the government’s announcement of the launch of the first four […]